SCHEMBL187662

SCHEMBL187662

O=C(/C=C\c1ccccc1)/C=C/c1ccccc1.O=C(/C=C\c1ccccc1)/C=C/c1ccccc1.[Pd]

nearest known ligand 0.95

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.95
CYP2C9 P11712 3/20 0.95
F3 P13726 3/20 0.95
CYP1A2 P05177 3/20 0.95
PLIN1 O60240 2/20 0.95
LMNA P02545 2/20 0.95
RECQL P46063 2/20 0.95
PLIN5 Q00G26 2/20 0.95
ABHD5 Q8WTS1 2/20 0.95
CYP2D6 P10635 2/20 0.95
ALDH1A1 P00352 2/20 0.95
SMN1; SMN2 Q16637 1/20 0.95
HDAC3 O15379 2/20 0.70
HDAC4 P56524 2/20 0.70
HDAC1 Q13547 2/20 0.70
HDAC2 Q92769 2/20 0.70
HDAC8 Q9BY41 2/20 0.70
HDAC6 Q9UBN7 2/20 0.70
TNKS O95271 1/20 0.70
HCAR2 Q8TDS4 1/20 0.70

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL546073 1.00 MAPT (0.95) MAPTCYP2C9F3CYP1A2PLIN1
SCHEMBL7512289 1.00 MAPT (0.95) MAPTCYP2C9F3CYP1A2PLIN1
SCHEMBL509571 1.00 MAPT (0.95) MAPTCYP2C9F3CYP1A2PLIN1
SCHEMBL1646390 1.00 MAPT (0.95) MAPTCYP2C9F3CYP1A2PLIN1
SCHEMBL5111 1.00 MAPT (0.95) MAPTCYP2C9F3CYP1A2PLIN1
SCHEMBL14832106 1.00 MAPT (0.95) MAPTCYP2C9F3CYP1A2PLIN1
SCHEMBL2438441 1.00 MAPT (0.95) MAPTCYP2C9F3CYP1A2PLIN1
SCHEMBL18039478 1.00 MAPT (0.95) MAPTCYP2C9F3CYP1A2PLIN1
SCHEMBL21879664 1.00 MAPT (0.95) MAPTCYP2C9F3CYP1A2PLIN1
SCHEMBL2639578 1.00 MAPT (0.95) MAPTCYP2C9F3CYP1A2PLIN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1396 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12577236-B2 Processes for preparation of Tezacaftor LAURUS LABS LIMITED (IN) 2026-03-17 US claimed
EP-4656639-A1 METHOD FOR THE PREPARATION OF IBOGAMINE AND PURIFICATION OF IBOGAMINE AND IBOGAMINE-TYPE COMPOUNDS Oeri, Hans (CA) 2025-12-03 EP claimed
EP-4624453-A1 METHOD FOR PREPARING CYCLOSULFONONE, AND INTERMEDIATES Lansheng Biotechnology Group Co., Ltd (CN) 2025-10-01 EP claimed
EP-4568984-A1 PROCESS FOR MANUFACTURING AN ANTIBIOTIC MACROCYCLIC PEPTIDE F. Hoffmann-La Roche AG (CH) 2025-06-18 EP claimed
WO-2024033278-A1 PROCESS FOR MANUFACTURING AN ANTIBIOTIC MACROCYCLIC PEPTIDE F. HOFFMANN-LA ROCHE AG (CH) 2024-02-15 WO claimed
US-11713286-B2 Butadiene telomerization catalyst preparation and use thereof DOW GLOBAL TECHNOLOGIES LLC (US) 2023-08-01 US claimed
CN-116217395-A Preparation method of beta-carbonyl compound 黄淮学院 2023-06-06 CN claimed
US-20220298097-A1 METHOD FOR PREPARING ORGANIC CARBOXYLIC ESTER BY USING COMBINED CATALYST OF ARYL BIDENTATE PHOSPHINE LIGAND NANJING CHENGZHI CLEAN ENERGY CO. LTD. (CN) 2022-09-22 US claimed
US-20220213006-A1 BUTADIENE TELOMERIZATION CATALYST PREPARATION AND USE THEREOF DOW GLOBAL TECHNOLOGIES LLC (US) 2022-07-07 US claimed
US-11345700-B2 Methods of preparing inhibitors of influenza viruses replication VERTEX PHARMACEUTICALS INCORPORATED (US) 2022-05-31 US claimed
US-20090282730-A1 METHOD AND COMPOSITION FOR IMPROVING FUEL COMBUSTION CARROLL & ASSOCIATES LLC 2009-11-19 US claimed
EP-2093275-A2 Method and composition for improving fuel combustion Carroll & Associates LLC (US) 2009-08-26 EP claimed
US-20080287663-A1 Process For Production Of 4-Biphenylyazetidin-2-Ones MICROBIA, INC. (US) 2008-11-20 US claimed
EP-1893571-A2 PROCESS FOR PRODUCTION OF 4-BIPHENYLYAZETIDIN-2-ONES Microbia Inc. (US) 2008-03-05 EP claimed
WO-2006122020-A2 PROCESS FOR PRODUCTION OF 4-BIPHENYLYAZETIDIN-2-ONES MICROBIA, INC. (US) 2006-11-16 WO claimed
WO-2005058813-A2 THIODIAZOLIDINEDIONE, OXAZOLIDINEDIONE AND DIAZOLIDINEDIONE DERIVATIVES AND THEIR USE AS ANTIDIABETIC AGENTS RANBAXY LABORATORIES LIMITED (IN) 2005-06-30 WO claimed
EP-1259475-A4 TRANSITION METAL-CATALYZED PROCESS FOR ADDITION OF AMINES TO CARBON-CARBON DOUBLE BONDS UNIV YALE (US) 2004-08-18 EP claimed
EP-1259475-A1 TRANSITION METAL-CATALYZED PROCESS FOR ADDITION OF AMINES TO CARBON-CARBON DOUBLE BONDS YALE UNIVERSITY (US) 2002-11-27 EP claimed
US-6384282-B2 CATALYST IS REACTION PRODUCT OF GROUP 8 METAL AND LIGAND YALE UNIVERSITY 2002-05-07 US claimed
WO-2001064620-A1 TRANSITION METAL-CATALYZED PROCESS FOR ADDITION OF AMINES TO CARBON-CARBON DOUBLE BONDS YALE UNIVERSITY (US) 2001-09-07 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080287663-A1 Process For Production Of 4-Biphenylyazetidin-2-Ones CYP4Z1, CYP4F12, CYP4F2 MAPT 4071/4885CYP2C9 64/4885F3 1073/4885
US-11713286-B2 Butadiene telomerization catalyst preparation and use thereof TELO2, TERT, TPR MAPT 1556/4885CYP2C9 2654/4885F3 3475/4885
US-12577236-B2 Processes for preparation of Tezacaftor CYP4A11, F9, CYP3A4 MAPT 3497/4885CYP2C9 23/4885F3 43/4885
US-20220213006-A1 BUTADIENE TELOMERIZATION CATALYST PREPARATION AND USE THEREOF TELO2, TERT, TPR MAPT 1556/4885CYP2C9 2654/4885F3 3475/4885
US-20220298097-A1 METHOD FOR PREPARING ORGANIC CARBOXYLIC ESTER BY USING COMBINED CATALYST OF ARYL BIDENTATE PHOSPHINE LIGAND POF1B, ADH1C, OSBP MAPT 4032/4885CYP2C9 240/4885F3 2505/4885
US-11345700-B2 Methods of preparing inhibitors of influenza viruses replication ZC3HAV1, ZC3HAV1L, POLR2H MAPT 3742/4885CYP2C9 1699/4885F3 865/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.